Atezolizumab and bevacizumab in advanced hepatocellular carcinoma: Real-world data.

被引：0
|
作者：
Bezalel, Nomi
Davidov, Yana
Likhter, Mariya
Ezra, Oranit Cohen
Inbar, Yael
Halpern, Naama
Ben Boursi
Beller, Tamar
Pery, Ron
Shmueli, Einat S.
Nachmany, Ido
Ben Ari, Ziv
Margalit, Ofer
机构：
[1] Sheba MC, Ramat Gan, Israel
[2] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel
[3] Sheba Med Ctr, Oncol Inst, Ramat Gan, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16167
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)
    Singal, A. G.
    Ozgurdal, K.
    Fan, X.
    Vassilev, Z.
    Chen, C-C.
    Multani, J. K.
    Zhou, Z.
    He, J.
    Pisa, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S867 - S867
  • [22] Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
    Iwamoto, Hideki
    Shimose, Shigeo
    Noda, Yu
    Shirono, Tomotake
    Niizeki, Takashi
    Nakano, Masahito
    Okamura, Shusuke
    Kamachi, Naoki
    Suzuki, Hiroyuki
    Sakai, Miwa
    Kajiwara, Akira
    Itano, Satoshi
    Tanaka, Masatoshi
    Yamaguchi, Taizo
    Kuromatsu, Ryoko
    Koga, Hironori
    Torimura, Takuji
    CANCERS, 2021, 13 (11)
  • [23] Potential faesability of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma: a real-world analysis
    Stefanini, Benedetta
    Bucci, Laura
    Santi, Valentina
    Reggidori, Nicola
    Rampoldi, Davide
    Lani, Lorenzo
    Trevisani, Franco
    JOURNAL OF HEPATOLOGY, 2022, 77 : S382 - S383
  • [24] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Timothy J. Brown
    Ronac Mamtani
    Phyllis A. Gimotty
    Thomas B. Karasic
    Yu-Xiao Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2345 - 2354
  • [25] Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world
    Zhang, Junwei
    Fang, Jinyu
    Xun, Ziyu
    Xu, Yiyao
    Lu, Xin
    Zhao, Haitao
    HEPATOLOGY, 2022, 76 (04) : E84 - E85
  • [26] Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study"
    Nishida, Naoshi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [27] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Sae Yumita
    Sadahisa Ogasawara
    Miyuki Nakagawa
    Susumu Maruta
    Tomomi Okubo
    Norio Itokawa
    Yotaro Iino
    Masamichi Obu
    Yuki Haga
    Atsuyoshi Seki
    Tadayoshi Kogure
    Takamasa Ishino
    Keita Ogawa
    Kisako Fujiwara
    Terunao Iwanaga
    Naoto Fujita
    Takafumi Sakuma
    Ryuta Kojima
    Hiroaki Kanzaki
    Keisuke Koroki
    Masanori Inoue
    Kazufumi Kobayashi
    Soichiro Kiyono
    Masato Nakamura
    Naoya Kanogawa
    Tomoko Saito
    Takayuki Kondo
    Ryo Nakagawa
    Shingo Nakamoto
    Ryosuke Muroyama
    Tetsuhiro Chiba
    Ei Itobayashi
    Masanori Atsukawa
    Yoshihiro Koma
    Ryosaku Azemoto
    Kenji Ito
    Hideaki Mizumoto
    Jun Kato
    Naoya Kato
    BMC Gastroenterology, 23
  • [28] Letter to the editor on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study"
    Wu, Meng-Che
    Chang, Hui-Chin
    Jhang, Yi-Sheng
    Gau, Shuo-Yan
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [29] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Yumita, Sae
    Ogasawara, Sadahisa
    Nakagawa, Miyuki
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kogure, Tadayoshi
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Inoue, Masanori
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Kato, Jun
    Kato, Naoya
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [30] Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Nakagawa, Miyuki
    Inoue, Masanori
    Ogasawara, Sadahisa
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kikuchi, Yasuharu
    Kogure, Tadayoshi
    Yumita, Sae
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Taida, Takashi
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Shinozaki, Masami
    Kato, Jun
    Kato, Naoya
    CANCER, 2023, 129 (04) : 590 - 599
12345